Focus: Rezolute is a public-stage biotechnology company focused on biologic therapies, primarily in oncology and metabolic disorders. The company operates as a clinical-stage biotech with a lean pipeline in Phase 2–3 development.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Rezolute to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rezolute
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rezolute's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Congenital Hyperinsulinism Pipeline Gains Momentum with Novel - openPR.com
Congenital Hyperinsulinism Pipeline Gains Momentum with Novel openPR.com
Handok's Partner Rezolute Retries Phase 3 Trial for Congenital Hyperinsulinism Drug - Seoul Economic Daily
Handok's Partner Rezolute Retries Phase 3 Trial for Congenital Hyperinsulinism Drug Seoul Economic Daily
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT) The Globe and Mail
Handok's Partner Rezolute Retries Phase 3 Trial for Congenital Hyperinsulinism Drug - Seoul Economic Daily
Handok's Partner Rezolute Retries Phase 3 Trial for Congenital Hyperinsulinism Drug Seoul Economic Daily
Handok Partner Rezolute Revives Phase 3 Trial for Hyperinsulinism Drug After FDA Meeting - Seoul Economic Daily
Handok Partner Rezolute Revives Phase 3 Trial for Hyperinsulinism Drug After FDA Meeting Seoul Economic Daily
Handok Partner Rezolute Revives Phase 3 Trial for Hyperinsulinism Drug After FDA Meeting - Seoul Economic Daily
Handok Partner Rezolute Revives Phase 3 Trial for Hyperinsulinism Drug After FDA Meeting Seoul Economic Daily
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo